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Abstract
Background. Acute renal failure (ARF) is a devastating
illness, especially when it occurs in various condi-
tions with impaired nitric oxide (NO) synthesis, such
as arterial hypertension, heart failure and some
renal diseases. We have directed our investigations to
effects of both angiotensin II (AII) and endothelin
(ET) receptor blockade associated with mild or
strong NO deficiency on haemodynamic, biochemical
and morphological parameters in experimental post-
ischaemic ARF.
Methods. In this study, we used bosentan (dual,
ETA/ETB-receptor antagonist), losartan (non-peptide,
competitive antagonist of type I AII receptor), and
NG-nitro-L-arginine methyl ester (L-NAME), inhibi-
tor of NO synthesis. Experiments were performed
in anaesthetized, adult male Wistar rats. The right
kidney was removed and the renal ischaemia was
performed by clamping the left renal artery for 45min.
Experimental groups received receptor antagonists
(bosentan or losartan) or vehicle (saline) in the femoral
vein 20min before, during and 20min after the
period of ischaemia. L-NAME was given as i.v. bolus
before each antagonist infusion. All parameters were
measured 24 h after reperfusion.
Results. Our results showed that strong NO blockade
overcame effects of both ET and AII receptor blockade
in experimental post-ischaemic ARF. In addition,
the AII receptor blockade had a harmful effect on
this condition, probably due to disturbed autoregula-
tory renal function. On the other hand, ET and AII
receptor blockade in mild NO blockade associated
with reperfusion injury, improves the most haemody-
namic, biochemical and morphological parameters.
Conclusions. We concluded that experimental post-
ischaemic ARF is neither AII nor ET mediated in case
of strong NO blockade, but, in more realistic condi-
tions of mild NO deficiency, these peptides represent
significant players whose receptor blockade expressed
relevant therapeutic potential.
Keywords: acute renal ischaemia; angiotensin;
endothelin; L-NAME; rats
Introduction
Acute renal failure (ARF) occurs frequently in
hospitalized patients, and it is frequently associated
with significant morbidity and mortality. Many
therapeutic strategies have been undertaken to prevent
acute renal injury, and, when ARF occurs, to improve
renal function and reduce mortality [1]. ARF in the
critical care setting is defined as the abrupt decline
in glomerular filtration rate (GFR), resulting from
ischaemic or toxic injury of the kidney. Renal failure is
often only one of several organ-system failures that are
present in intensive care patient population.
Recent evidence suggests that there are several
factors involved in the initiation and maintenance of
ARF. These factors include a decrease of glomerular
capillary permeability, back-leak of glomerular filtrate,
tubular obstruction, intrarenal vasoconstriction, etc.
Both sublethal and lethal cell injuries have been found
in ARF, the latter leads either to necrosis or to
apoptosis. The finding that balance between endothelin
(ET) and endothelium-derived nitric oxide (NO) is
shifted in ARF, in favour of ET, which then leads to
intrarenal vasoconstriction, is receiving considerable
attention as a major contribution to the understanding
of the pathogenesis of ARF [2]. It yields therapeutic
manoeuvres targeted at restoring this balance, and
relieving intrarenal vasoconstriction. Recent observa-
tions indicate that angiotensin II (AII), ET and
NO may play an important role in the progression
of HgCl2-induced ARF through the acceleration of
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proximal tubule epithelial cell injury and the deteriora-
tion of glomerular haemodynamics [3]. AII and ET-1,
major endogenous vasoconstrictors in ARF, can
modulate the effects of each other, and therefore
contribute to general balance of vasoconstrictor-
vasodilatator modulation in ARF. On the other
hand, recent findings are consistent with a rationale
for administration of both ET and AII blockers
in treating NO-deficient conditions, such as arterial
hypertension, heart failure, and chronic renal dis-
eases [4]. Regarding that, the aim of our study was
to evaluate the interaction of these vasoconstrictors
on haemodynamic, biochemical and histological
parameters in experimental post-ischaemic ARF asso-
ciated with mild or strong NO deficiency.
Materials and methods
Materials
Male adult Wistar rats, weighing about 300 g, were bred in
the Institute for Medical Research, Belgrade and fed with a
standard chow for laboratory rats (Veterinarski zavod,
Subotica, Serbia). All animal experiments were conducted
in accordance with local institutional guidelines for the care
and use of laboratory animals. The investigation also con-
formed to the principles and guidelines of Conseil de
l’Europe (published in the Official Daily N. L358/1-358/6,
18 December 1986), the US National Institutes of Health
(Guide for the Care and Use of Laboratory Animals, NIH
publication no. 85-23), and the Canadian Council on Animal
Care (CCAC).
We used the following:
(i) Bosentan (Ro47-0203/001;4-tert-butyl-N-[6-(2-hydroxy-
ethoxy)-5-(2-metoxy-phenoxy)-2,2’-bispyrimidine-4-yl]-
benzenesulphonamide sodium salt), non-peptide,
potent and mixed ETA and ETB-receptor antagonist
(gift of Dr Martine Clozel, Actelion Ltd, Allschwil,
Switzerland).
(ii) Losartan (DUP 153), AII type 1 receptor blocker was
obtained from Du Pont, (Wilmington, DE, USA).
(iii) L-NAME (NG-L-Arginine Methyl Ester, Sigma); a NO
synthesis inhibitor.
Experimental protocol
All our experiments were performed in anaesthetized (35mg/
kg b.m. sodium pentobarbital; intra peritoneal—i.p.) rats.
Experimental groups and model of ARF
The animals were divided into the following experimental
groups: L-NAMEþARF, L-NAMEþARFþ bosentan and
L-NAMEþARFþ losartan. There were two control groups,
control sham-operated rats (SHAM) and control rats with
ARF (ARF control). In all ARF groups, the right kidney was
removed, and the rats were subjected to renal ischaemia by
clamping the left renal artery for 45min. The sham group
consisted of right nephrectomized rats and received the
vehicle via the same route as all other experimental groups.
All rats were placed in individual metabolic cages immedi-
ately after infusion and surgery procedures.
Investigation was designed in two separately performed
set-ups, with high (10mg/kg b.m.) and with low (3mg/
kg b.m.) dosage of the L-NAME infusion, combined with
adequate receptor antagonist treatment or vehicle. The
experimental groups received receptor antagonists bosentan
(10mg/kg b.m.) and losartan (10mg/kg b.m.), or vehicle
(saline) in the femoral vein 20min before, during and 20min
after the period of ischaemia. This dose of bosentan was used
according to the studies of Closel et al. [5], where the initial
depressor and sustained pressor response to ET-1 was
abolished and the maximal effects of bosentan were usually
reached at 10mg/kg i.v. bolus. The applied dose of losartan
represents the most commonly used dose for similar
cardiovascular experiments. Thus, Ortiz et al. [6] published
that losartan in a dose of 10mg/kg i.v. bolus blocked almost
completely (95.6 2.3%) the pressor effects of a bolus dose
of 250 ng/kg of AII for at least 60min.
L-NAME was given as i.v. bolus before antagonists or
vehicle infusion. Inhibition of NO synthesis by L-NAME
blocks all three NO synthase isoforms, resulting in hyperten-
sion in rats [7]. The dose of 10mg/kg i.v. bolus was
applied according to results published by Ortiz et al. [6],
which revealed that this dose produces the maximum blood
pressure and renal blood flow effects. On the other hand,
the dose of 3mg/kg i.v. bolus, as an example of mild NO
deficiency, was chosen concerning works of Wang [8] and
Filep [9], where this dose had significant effects on blood
presssure and renal function in animal models.
Haemodynamic measurements 24 h after reperfusion
Haemodynamic parameters were measured after the 24 h
urine collection period. All animals were anaesthetized
(35mg/kg sodium pentobarbital; i.p.). Mean arterial pressure
(MAP) and heart rate (HR) were determined directly
through a femoral artery catheter (PE-50, Clay-Adams,
Parsippany, NY, USA), using a low-volume displacement
transducer (P23 Db, Statham, Oxnard, CA, USA) and
recorded on a direct writing recorder.
Cardiac output (CO) was determined by modified
Coleman’s application [10] of the dye dilution technique as
previously described [11]. Total vascular resistance (TVR)
was calculated by dividing MAP by CO and expressed as
mmHg min kg/ml.
For the blood flow measurement, the left renal artery was
gently separated. An ultrasonic flow probe (1RB, internal
diameter¼ 1mm) was placed around the artery for the
measurement of renal blood flow (RBF), using a Transonic
T106 Small Animal Flowmeter (Transonic System Inc.,
Ithaca, NY, USA). Renal vascular resistance (RVR) was
calculated by dividing MAP by renal blood flow and
expressed as mmHg min kg/ml.
Biochemical measurements 24 h after reperfusion
Urinary and plasma concentrations of creatinine were
determined using a Beckman 42 spectrophotometer.
Concentrations of sodium (Naþ) and potassium (Kþ) in the
plasma and urine were measured using IL 943-flame
photometer (Instrumentation Laboratory, Milan, Italy).
Plasma and urine protein concentrations were measured
using Randox commercial test (Crumlin, Antrim, UK).
Standard formula was used to calculate creatinine clearance.
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Fractional excretion of electrolytes was calculated as a per-
centage of creatinine clearance. Reabsorption rates of Naþ
and water at tubular sites were calculated from the formulae
quoted in Kusaka et al. [12]. Renal failure index was also
calculated.
Histological examination
The left kidney was examined morphologically, 24 h after the
period of reperfusion. The renal tissue was fixed in 10%
buffered formalin solution. Later, the kidney was dehydrated
in alcohol, blocked in paraffin wax, and 5mm thick sections
were sliced and stained by haematoxylin eosine (H&E) and
by periodic acid-Schiff (PAS) reaction. By light microscopy
the following parameters were semi-quantitatively evaluated
on a scale from 0 to 4 according to the degree of lesions:
intensity and spread of tubular necrosis, number of intra-
luminal cast formations, swelling and vacuolization of cells,
loss of luminal membrane or brush borders, tubular dilata-
tion, interstitial oedema and separation of cells from
tubular basal membrane. The severity of congestion i.e. the
accumulation of red blood cells in glomeruli, peritubular
capillaries and intrarenal veins, was graded on a scale from
1 to 3, as described by Mandal et al. [13,14]. The sum of these
changes represented the histopathological score for compar-
ison between groups.
Statistical analysis
The results are expressed as mean SEM. One-way analysis
of variance (ANOVA) was applied. When the ANOVA
results were significant, Bonferroni’s t-test was used to
determine the level of significance and a P-value <0.05 was




ARF groups treated with 10mg/kg b.m. L-NAME. The
MAP was significantly increased in all L-NAME-
treated groups in comparison with both control
groups. HR was significantly lower in L-NAMEþ
ARF and L-NAMEþARFþbosentan groups, how-
ever, in the L-NAMEþARFþ losartan group HR
was similar to the SHAM (Table 1).
The CO was not different between experimental
groups, but it was markedly reduced in comparison
with the controls. Although TVR was increased in all
L-NAME treated groups, it was significantly higher
only in the L-NAMEþARFþ bosentan group com-
pared with both control groups (0.54 0.06 vs
0.34 0.04/0.28 0.02mmHg min kg/ml; Table 1).
After ARF induction, RBF was dramatically
reduced in all ARF groups independently of treatment
procedure. The L-NAME administration increased
RVR in all experimental groups in comparison with
SHAM (Figure 1).
ARF groups treated with 3mg/kg b.m. L-NAME. The
MAP was significantly increased in the L-NAMEþ
ARF group in comparison with control groups
(125.00 6.41 vs 91.11 2.72/95.18 2.85mmHg;
Table 2). However, bosentan and losartan decreased
it approximately to control values. HR was signifi-
cantly lower in all L-NAME-treated groups as
compared with the controls (Table 2).
The CO was not different between the groups. TVR
was significantly increased in the L-NAMEþARF
group vs ARF control group (0.47 0.04 vs
0.28 0.02mmHgmin kg/ml; Table 2).
Table 1. Haemodynamic parameters and histopathological score after 10mg/kg b.m. L-NAME infusion




SHAM (n¼ 9) 91.11 2.72 374.44 17.00 307.00 32.00 0.34 0.04 0.71 0.18
ARF control (n¼ 11) 95.18 2.82 335.00 13.19 331.00 24.40 0.28 0.02 9.75 0.70
L-NAMEþARF (n¼ 2) 126.15 3.53 290.00 15.02 267.50 28.70 0.47 0.06 10.67 0.56
L-NAMEþBosþARF (n¼ 2) 129.15 2.63, 302.75 17.83 244.00 22.40 0.54 0.06, 8.22 1.00
L-NAMEþLosþARF (n¼ 0) 117.38 4.65, 372.50 10.65 284.50 19.90 0.45 0.04 12.00 0.53,y
P< 0.05 compared with sham; P< 0.05 compared with ARF control.
yP< 0.05 compared to L-NAMEþBosþARF































































Fig. 1. Renal blood flow and renal vascular resistance in experi-
mental groups after 10mg/kg b.m. L-NAME infusion.
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Renal ischaemia markedly diminished RBF in all
ARF groups as compared with SHAM. L-NAME
or receptor antagonists had no influence on the RBF
value (Figure 2). RVR was significantly higher in
the L-NAMEþARF group compared to ARF con-
trol (33.74 6.71 vs 15.07 2.40mmHgmin kg/ml).
However, bosentan and losartan reduced it almost to
the value of ARF control group (Table 2).
Biochemical parameters
ARF groups treated with 10mg/kg b.m.
L-NAME. GFR, presented as an endogenous creati-
nine clearance, fell in all ARF groups 24 h after the
period of ischaemia. In the L-NAMEþARF group,
decrease in GFR was smaller as compared with other
groups with ARF, but not statistically significant
(Table 3).
ARF induced higher fractional excretion of sodium
ðFENa
þÞ, however, FENa
þ was strongly increased in
the L-NAMEþARF groups treated with antagonists
(Table 3).
The value of the urine protein excretion (UPE) was
doubled in the ARF control with respect to sham
animals (278.31 46.67 vs 130.51 6.91mg/24 h/kg)
and it was similar to the values of all experimental
groups (Table 3).
Plasma potassium concentration ðPK
þÞ was signifi-
cantly increased in the group of L-NAMEþARFþ
losartan as compared with SHAM and ARF control
(7.17 0.75 vs 4.31 0.15/4.93 0.15mmol/l). Other
groups showed no relevant differences (Table 3).
Renal failure index (RFI) notably rose after ARF
and was extremely high in both groups with receptor
antagonist infusion (Table 3).
ARF groups treated with 3mg/kg b.m. L-NAME. GFR
in the L-NAMEþARF group was similar to the ARF
control group. Although both applied receptor antago-
nists improved GFR, only bosentan revealed signifi-
cant improvement as compared with ARF control
(1.74 0.39 vs 0.54 0.17ml/min/kg; Table 4).
Bosentan and losartan treatment reduced FENa
þ
as compared with L-NAMEþARF group, and signifi-
cantly reduced it as compared with ARF control group
(Table 4).
UPE had similar values in all L-NAME treated
groups but it was markedly lower compared with
the ARF control. PK
þ showed no relevant differences
between the groups. RFI was reduced moderately in
bosentan- and losartan-treated groups, as compared
with L-NAMEþARF group (Table 4).
Histological studies
Morphological examination of the renal tissue revealed
significant differences between experimental groups
of animals.
Glomeruli, tubulointerstitium and blood vessels of
the sham-operated animals were without any changes
on the light microscopy examination. In a few kidney
specimens, only a small number of PAS-positive casts
were observed in the tubular lumen (Figure 3A).
Kidneys in the ARF control group showed dilata-
tion of some segments of proximal and distal tubules
with or without loss of brush border of proximal
tubular epithelium. Swelling of some proximal tubular
epithelial cells was present. The most prominent lesions
were widespread tubular necrosis in the cortico-
medullary zone and a huge number of PAS-positive
casts in the lumina of distal tubuli and collecting ducts.
The intensity of interstitial oedema varied among
Table 2. Haemodynamic parameters and histopathological score after 3mg/kg b.m. L-NAME infusion




SHAM (n¼ 9) 91.11 2.72 374.44 17.00 307.00 32.00 0.34 0.04 0.71 0.18
ARF control (n¼ 11) 95.18 2.85 335.00 13.19 331.00 24.40 0.28 0.02 9.75 0.70
L-NAMEþARF (n¼ 8) 125 6.41, 297.50 7 273.80 12.20 0.47 0.04 10.50 0.34
L-NAMEþBosþARF (n¼ 8) 102.50 6.90 305 1.89 281.50 24.30 0.38 0.04 5.71 0.29,,
L-NAMEþLosþARF (n¼ 9) 89.44 5.46 297.78 6.41 231.70 28.10 0.42 0.04 6.50 0.43,,
P< 0.05 compared with sham; P< 0.05 compared with ARF control; and P< 0.05 compared with L-NAMEþARF.









* p < 0.05 vs. SHAM
# p < 0.05 vs. ARFcontrol





















































Fig. 2. Renal blood flow and renal vascular resistance in experi-
mental groups after 3mg/kg b.m. L-NAME infusion.
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specimens in this group. Glomeruli and blood vessels
were the same as in the sham-operated group
(Figure 3B).
ARF groups treated with 10mg/kg b.m. L-NAME. In
the L-NAMEþARF group, the picture was similar to
the ARF control, with more widespread and intensive
tubular necrosis (Figure 3C).
In some specimens of the L-NAMEþARFþ
bosentan group, tubular necrosis in corticomedullary
junction was less intense and less widespread in
comparison with the control animals with ARF
(Figure 3D).
Unexpectedly, kidney specimens of L-NAMEþ
ARFþ losartan group showed intensive and more
widespread tubular necrosis in the corticomedullary
region. Tubular dilatation and a huge number of
PAS-positive casts in collecting ducts were more
prominent as compared with the ARF control group
(Figure 3E).
ARF groups treated with 3mg/kg b.m.
L-NAME. Confluent tubular necrosis in the cortico-
medullary zone, a huge number of PAS-positive casts
in lumina of tubuli and collecting ducts and tubular
dilatation with pronounced loss of brush border of
proximal tubular epithelium, were all present in the
L-NAMEþARF group. Focal tubular necrosis and
PAS-positive luminal casts in the cortex were also
noticed in this group (Figure 4A).
Interestingly, in the L-NAMEþARFþ bosentan
group, tubular necrosis was less widespread and pre-
dominantly focal, proximal tubular dilatation was
slightly prominent, and casts formation was very
rarely present. The loss of brush border of proximal
tubular epithelium was less evident (Figure 4B).
The morphology of the kidneys of the L-NAMEþ
ARFþ losartan group was similar to the kidneys of
the L-NAMEþARFþ bosentan group, with more
prominent tubular dilatation in the corticomedullary
zone (Figure 4C).
Discussion
Recent observations indicate that NO has a crucial
role in the pathogenesis of ischaemic ARF, and that
spontaneous NO donors may be clinically effective
in ischaemic ARF [15,16]. However, ET-1 plays a
significant role in the pathogenesis of ischaemic ARF
[17], in renal failure that occurs in patients with acute
liver failure [18], as well as in haemodynamic events in
radiocontrast-induced nephropathy [19]. ET-1 receptor
antagonists provide a potential therapeutic tool due to
the fact that bosentan could attenuate cyclosporine A
renal toxicity in a double-blind, placebo-controlled
crossover study [20]. Also, it has been demonstrated
that AT1 receptor blockade accelerates recovery of
renal function in the post-ischaemic kidney [21].
In the present study, bolus administration of
10mg/kg b.m. L-NAME increased both MAP and
TVR, similarly to long-term L-NAME application
in the studies reported by Jerkić et al. [16]. ET and AII
receptor blockades had no influence on those param-
eters in the mentioned conditions. Although MAP














SHAM (n¼ 9) 2.22 0.23 1.18 0.56 130.51 6.91 4.31 0.15 0.23 0.10
ARF control (n¼ 11) 0.23 0.03 11.04 2.43 278.31 46.67 4.93 0.29 2.17 0.48
L-NAMEþARF (n¼ 8) 0.54 0.17 4.65 3.01 95.70 13.70 4.09 0.14 6.2 3.90
L-NAMEþBosþARF (n¼ 8) 1.74 0.39 1.64 0.55 93.20 14.60 4.54 0.35 2.16 0.70
L-NAMEþLosþARF (n¼ 9) 1.06 0.56 2.06 0.90 78.80 18.90 4.37 0.29 2.76 1.22
P< 0.05 compared to sham; P< 0.05 compared with ARF control.















SHAM (n¼ 9) 2.22 0.23 1.18 0.56 130.51 6.91 4.31 0.15 0.23 0.10
ARF control (n¼ 11) 0.23 0.03 11.04 2.43 278.31 46.67 4.93 0.29 2.17 0.48
L-NAMEþARF (n¼ 12) 0.63 0.20 9.73 3.61 172.86 14.69 5.47 0.54 1.88 0.66
L-NAMEþBosþARF (n¼ 12) 0.17 0.03 49.44 10.28 313.74 44.94 6.03 0.39 9.19 2.14
L-NAMEþLosþARF (n¼ 10) 0.14 0.026 74.31 21.60,, 333.62 108.03 7.17 0.75, 14.95 4.14,,
P< 0.05 compared with sham; P< 0.05 compared with ARF control; P< 0.05 compared with L-NAMEþARF.
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had a tendency to decrease in the L-NAMEþARFþ
losartan group in comparison with other L-NAME
groups, this resultwas not statistically significant. This is
in accordance with results of Turskstra et al. [22] who
showed that short-term NO synthase (NOS) blockade
caused a dose-dependent pressor and renal vasocon-
strictor response and that AT1-receptor blockade
restored systemic pressor and renal vasoconstrictive
effects of mild NOS inhibition, but failed to exert
vasorelaxation during strong NOS blockade. Also, the
mentioned results supported our findings that after
3mg/kg b.m. L-NAME infusion MAP significantly
fell in losartan-treated animals with ARF. In the
L-NAMEþARFþ bosentan group, after strong NO
blockade we obtained MAP values similar to the ARF
group treatedwithL-NAMEalone.Filep [9] has demon-
strated that the pressor effect of L-NAME (given in






Fig. 3. Histology of the kidney after 10mg/kg b.m. L-NAME infusion; (A) a normal shape of the glomerulus and tubulointerstitium in the
sham-operated animals (B) glomerulus, tubular dilatation and necrosis, PAS-positive casts in the ARF control group; (C) intensive tubular
necrosis, tubular dilatation and interstitial oedema in the L-NAMEþARF group; (D) moderately intensive tubular necrosis in bosentan-
treated rats; (E) intensive and widespread tubular necrosis, tubular dilatation and a huge number of PAS-positive casts in losartan-treated
rats (PASX320).
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bosentan in normal Wistar rats, which is in correspon-
dence with the reduction ofMAP in our results obtained
by administration of 3mg/kg b.m. L-NAME together
with bosentan in ischaemic rats. On the other hand,
resultsofQiuetal. [23]have shownthatbosentanblunted
(but did not normalize) the rise in MAP after acute
L-NAME application in the dosage of 10mg/kg b.m. in
chronically catheterized Spargue-Dawley rats. The
absence of this effect in our experiment could be
explained by different rat strain and by production of
other vasoconstrictors in post-ischaemic condition.
Present study revealed that renal haemodynamic
alterations induced by ARF accompanied with NO
synthesis inhibition by L-NAME, are more intensive
than those induced by ARF alone. The worsening
of ischaemia-induced renal vasoconstriction caused by
L-NAME suggests that endogenous NO is functionally
present and may be an important mediator in the
regulation of renal haemodynamics in the post-
ischaemic ARF. Conger et al. [24] demonstrated in
1980 that endothelium-dependent relaxation was
clearly impaired after ischaemia, but their later publi-
cation [25] disclosed that attenuated response to
endothelium-dependent vasodilators could not be
interpreted due to decrease of NOS activity. Namely,
the authors suggest that the increase of NOS activity
is a response to ischaemia-induced renal vasocon-
strictor activity. In our experiment, both ET and AII
receptor antagonists slightly improve RBF after strong
NOS blockade compared with the group treated only
with L-NAME, but strongly increased RBF after
moderate NO deficiency. Qiu and Baylis [26] suggest
that endogenous ET and AII partially mediate the
glomerular haemodynamic response to acute NOS
inhibition. The authors also indicate that actions of ET
and AII are mainly additive, because vasoconstrictive
responses to acute NOS inhibition are mostly pre-
vented when both vasoconstrictor systems are
blocked. In addition, results of Fortepiani et al. [27]
have demonstrated that treatment with bosentan
did not attenuate the arterial hypertension of the
L-NAME-treated rats, but normalized their GFR
and RBF. Our results demonstrated that it was not
the case in post-ischaemic conditions associated
with strong NO inhibition, but in the condition of
mild NO deficiency, bosentan clearly improved RBF
and GFR. Impairment of GFR and RBF induced by
strong NOS blockade in our bosentan-treated rats
could be partially explained by complete blockade of
ET-B receptors in addition to NO inhibition, because
enhanced auto-regulatory renal blood flow efficiency
due to NO inhibition includes preferential activation
of the ET-B receptors [28].
Twenty-four hours after ARF induction, GFR
was drastically reduced followed by enhanced FENa
þ.
These biochemical parameters were not influenced
by inhibition of NOS induced by L-NAME (10mg/kg
b.m.) alone or in association with receptor antagonists.
Results of Treeck et al. [29] have shown that after
pre-treatment with L-NAME (19mg/kg b.m.), losartan




Fig. 4. Histology of the kidney after 3mg/kg b.m. L-NAME
infusion; (A) focal necrotic arrays, a huge number of PAS-positive
casts in collecting ducts, tubular dilatation with pronounced
loss of the brush border of proximal tubular epithelium in the
cortex of the L-NAMEþARF group; (B) slightly prominent
proximal tubular dilatation, rarely casts formation and less
pronounced loss of brush border of the proximal tubular epithelium
in L-NAMEþARFþ bosentan group; (C) more pronounced
tubular dilatation in the corticomedullary zone of the
L-NAMEþARFþ losartan group.
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somehow in agreement with our results, obtained by
mild NO blockade associated with ARF. Otherwise,
our results with strong NO deficiency suggest, similar
to the observation of Jover et al. [30], that AII, through
its effects on AT1 receptors, may play an important
role in the maintenance of L-NAME hypertension,
but regulation of both GFR and filtration fraction
encompasses non-AII-mediated mechanisms. In addi-
tion, tubular cell injury which is associated with ARF,
additionally diminished regular vascular response to
vasoactive substances.
Increase of FENa
þ in both groups treated with
receptor antagonists could be a consequence of
receptor blockade and tubular cell injury. It is well
known that AII has a dominant role in sodium
retention due to stimulation of aldosterone secretion
from the adrenal cortex and due to action on
intraluminal AT1 receptors of proximal and distal
tubules [31]. Blockade of AT1 and ET receptors, as
well as sublethal and necrotic injuries of tubular cells
(caused by ischaemia), could be the reason for the
noticeable increase of RFI and increase of PK
þ.
Results of Jerkić et al. [17] have shown that losartan
(10mg/kg b.m.) significantly reduced UPE after
reperfusion injury in Wistar rats. Results of the present
study demonstrate that mild NO inhibition leads to
diminished UPE independently of receptor blockades.
Slight improvement of morphological renal changes
in bosentan-treated rats did not support a crucial role
of ET in induction of kidney lesions caused by strong
NO inhibition in post-ischaemic ARF. Our previous
results have shown that ET-1 dual receptor blockade
improved histopathological changes induced by
ischaemia in the kidney of normotensive Wistar rats
[17]. Other authors reported also that ET receptor
antagonists improve both renal function and renal
histological features in the setting of renal ischaemia-
reperfusion injury [32,33]. In the present study, our
results show that ET peptides probably do have an
important role in inducing renal damages caused
by mild NO deficiency, because dual ET blockade
improves the most morphological parameters in the
ischaemic kidney.
Prominent tubular necrosis in the corticomedullary
region, tubular dilatation and a huge number of PAS-
positive casts in collecting ducts in rats treated with
losartan, indicate harmful effects of AII receptor
blockade in ARF associated with strong NO blockade.
However, our previous results [17] have shown that
losartan had no beneficial effects on renal function
and morphology in normotensive rats with ischaemic
ARF. In addition, there is a well-known precaution
for use of AII blockade in patients with ARF in clinical
units, because this blockade reduced blood pressure
and GFR. In the present study, blood pressure in the
losartan-treated group was high, but GFR was still
significantly reduced. Taken together, these results
indicate that the most important consequence of
strong NO deficiency in the post-ischaemic kidney is
renal vasoconstriction, which could be suppressed
neither by dual ET receptor blockade nor by AT1
receptor blockade. In our opinion, strong NO defi-
ciency is a main reason for non-improved kidney
function and morphology in the present experimental
conditions. Additionally, NO participates in several
vital processes in the kidney which encompass regula-
tion of glomerular and medullary haemodynamics,
tubuloglomerular feedback response, renin release,
extracellular fluid volume [34] and regulation of
Naþ-Kþ-ATPase, Naþ/Hþ exchangers and para-
cellular permeability of proximal tubular cells [35].
Kontogiannis and Burns [21] have demonstrated that
renal ischaemia–reperfusion injury caused an early
increase of intrarenal AII levels and that blockade
of AT1 receptors with losartan accelerated recovery
of renal function after bilateral renal pedicle occlusion
for 60min. These results are in concordance with
results of the present study, which show that AII partly
contributes to functional disturbance and morpho-
logical lesions after moderate NO deficiency in
ischaemic kidney.
In summary, our results have shown that strong
NO blockade overcomes the effects of both ET and
AII receptor blockade in experimental post-ischaemic
ARF. Thus, we could conclude that renal vasocon-
striction, decline of kidney function and morpho-
logical lesions, due to strong NOS blockade, were not
mediated either by ET-1 or by AII in post-ischaemic
ARF. Also, as a consequence of disturbed tubuloglo-
merular feedback response, additional AII receptor
blockade may be harmful in the condition of strong
NO deficiency and ARF. Non-selective ET receptor
blockade excludes ET-B receptors from enhanced
auto-regulatory renal blood flow efficiency due to
NO inhibition and therefore contributes to further
impairment of renal function and morphology. Since
ET and AII receptor blockade in more realistic mild
NO blockade associated with reperfusion injury
improved the most haemodynamic, biochemical and
morphological parameters, this could have relevant
therapeutic potential.
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